Profile data is unavailable for this security.
About the company
Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.
- Revenue in CAD (TTM)9.63m
- Net income in CAD-4.71m
- Incorporated2016
- Employees12.00
- LocationCeapro Inc7824 51 Ave NWEDMONTON T6E 6W2CanadaCAN
- Phone+1 (780) 421-4555
- Fax+1 (780) 421-1320
- Websitehttps://www.ceapro.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sirona Biochem Corp | 36.35k | -2.65m | 17.95m | -- | -- | -- | -- | 493.68 | -0.0105 | -0.0105 | 0.0001 | -0.011 | 0.0492 | -- | 7.70 | -- | -358.70 | -173.09 | -- | -383.49 | -- | -- | -7,297.85 | -1,405.28 | -- | -9.04 | -- | -- | -94.82 | -51.37 | 28.52 | -- | -- | -- |
| Kane Biotech Inc | 148.98k | -4.56m | 18.45m | -- | -- | -- | -- | 123.85 | -0.0359 | -0.0396 | 0.0012 | -0.0801 | 0.0264 | 0.0779 | 0.9169 | -- | -80.74 | -77.89 | -- | -- | 73.48 | 43.27 | -3,062.39 | -241.85 | 0.3188 | -2.78 | 10.99 | -- | -94.42 | -20.26 | -17.29 | -- | -19.41 | -- |
| Cytophage Technologies Ltd | 0.00 | -4.64m | 19.34m | -- | -- | 8.15 | -- | -- | -0.5489 | -0.5489 | 0.00 | 0.0442 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -165.33 | 0.8283 | -- | -- | -- | -25.88 | -- | -- | -- |
| Ceapro Inc | 9.63m | -4.71m | 19.57m | 12.00 | -- | 0.7027 | -- | 2.03 | -0.0602 | -0.0602 | 0.1231 | 0.3558 | 0.2785 | 1.25 | 6.45 | -- | -13.62 | 2.46 | -14.42 | 2.59 | 41.07 | 52.27 | -48.89 | 5.13 | 5.49 | -39.49 | 0.0747 | 0.00 | -48.87 | -3.64 | -207.09 | -- | -3.60 | -- |
| Rubicon Organics Inc | 40.12m | -1.82m | 20.50m | 180.00 | -- | 0.5412 | 15.47 | 0.5111 | -0.0323 | -0.0323 | 0.7107 | 0.6744 | 0.7228 | 1.23 | 9.92 | 222,869.30 | -3.29 | -18.76 | -4.25 | -24.93 | 63.27 | 55.64 | -4.55 | -42.42 | 0.9322 | 15.08 | 0.2154 | -- | 12.95 | -- | 52.71 | -- | -21.38 | -- |
